- Home
- ACLX vs ARWR Comparison
ACLX vs ARWR Comparison
Compare ACLX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- ARWR
- Stock Information
- Founded
- ACLX 2015
- ARWR 2003
- Country
- ACLX United States
- ARWR United States
- Employees
- ACLX N/A
- ARWR N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- ARWR Health Care
- Exchange
- ACLX Nasdaq
- ARWR Nasdaq
- Market Cap
- ACLX 4.4B
- ARWR 5.1B
- IPO Year
- ACLX 2022
- ARWR 1993
- Fundamental
- Price
- ACLX $85.09
- ARWR $38.05
- Analyst Decision
- ACLX Strong Buy
- ARWR Strong Buy
- Analyst Count
- ACLX 12
- ARWR 8
- Target Price
- ACLX $113.08
- ARWR $47.75
- AVG Volume (30 Days)
- ACLX 548.8K
- ARWR 1.8M
- Earning Date
- ACLX 11-07-2025
- ARWR 11-25-2025
- Dividend Yield
- ACLX N/A
- ARWR N/A
- EPS Growth
- ACLX N/A
- ARWR N/A
- EPS
- ACLX N/A
- ARWR N/A
- Revenue
- ACLX $56,979,000.00
- ARWR $572,976,000.00
- Revenue This Year
- ACLX N/A
- ARWR $21,287.22
- Revenue Next Year
- ACLX $210.73
- ARWR N/A
- P/E Ratio
- ACLX N/A
- ARWR N/A
- Revenue Growth
- ACLX N/A
- ARWR 2816.20
- 52 Week Low
- ACLX $47.86
- ARWR $9.57
- 52 Week High
- ACLX $107.37
- ARWR $40.29
- Technical
- Relative Strength Index (RSI)
- ACLX 54.28
- ARWR 63.20
- Support Level
- ACLX $82.64
- ARWR $36.73
- Resistance Level
- ACLX $94.07
- ARWR $39.56
- Average True Range (ATR)
- ACLX 3.64
- ARWR 1.72
- MACD
- ACLX -0.81
- ARWR -0.32
- Stochastic Oscillator
- ACLX 21.43
- ARWR 60.56
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.